Pluri Inc. (PLUR) Gross Margin
- Gross margin · 12 months: Value 44.59%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 44.59% | Gross profit / revenue. Period ending 2026-06-30. $453.00K ÷ $1.02M × 100 ≈ 44.59% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 453.00K USD | Gross Profit |
| Revenue | 1.02M USD | |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $453.00K | $1.02M | (m) | 44.59% |
| 2026-03-31 | $464.00K | $1.08M | (m) | 43.00% |
| 2025-12-31 | $544.00K | $1.34M | (m) | 40.63% |
| 2025-09-30 | $569.00K | $1.33M | (m) | 42.91% |
| 2025-06-30 | $654.00K | $1.34M | (m) | 48.95% |
| 2025-03-31 | $539.00K | $1.03M | (m) | 52.13% |
| 2024-12-31 | $474.00K | $678.00K | (m) | 69.91% |
| 2024-09-30 | $468.00K | $598.00K | (m) | 78.26% |
| 2024-06-30 | $322.00K | $326.00K | (m) | 98.77% |
| 2024-03-31 | (m) | $341.00K | (m) | (m) |
| 2023-12-31 | (m) | $357.00K | (m) | (m) |
| 2023-09-30 | (m) | $254.00K | (m) | (m) |
| 2023-06-30 | $278.00K | $287.00K | (m) | 96.86% |
| 2023-03-31 | (m) | $176.00K | (m) | (m) |
| 2022-12-31 | (m) | $323.00K | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $234.00K | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) |
| 2020-06-30 | $23.00K | $23.00K | (m) | 100.00% |
| 2020-03-31 | $22.00K | $23.00K | (m) | 95.65% |
| 2019-12-31 | $22.00K | $23.00K | (m) | 95.65% |
| 2019-06-30 | $52.00K | $54.00K | (m) | 96.30% |
| 2019-03-31 | $52.00K | $54.00K | (m) | 96.30% |
| 2018-12-31 | $52.00K | $54.00K | (m) | 96.30% |
| 2018-09-30 | $52.00K | $54.00K | (m) | 96.30% |
| 2018-06-30 | $48.00K | $50.00K | (m) | 96.00% |
| 2018-03-31 | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) |
| 2016-06-30 | $2.75M | $2.85M | (m) | 96.49% |
| 2016-03-31 | $2.84M | $2.94M | (m) | 96.50% |
| 2015-12-31 | $2.93M | $3.04M | (m) | 96.51% |
| 2015-09-30 | $366.00K | $379.00K | (m) | 96.57% |
| 2015-06-30 | $366.00K | $379.00K | (m) | 96.57% |
| 2015-03-31 | $367.00K | $379.00K | (m) | 96.83% |
| 2014-12-31 | $367.00K | $379.00K | (m) | 96.83% |
| 2014-09-30 | $368.00K | $379.00K | (m) | 97.10% |
| 2014-06-30 | $368.00K | $379.00K | (m) | 97.10% |
| 2014-03-31 | $369.00K | $380.00K | (m) | 97.11% |
| 2013-12-31 | $465.00K | $479.00K | (m) | 97.08% |
| 2013-09-30 | $562.00K | $579.00K | (m) | 97.06% |
| 2013-06-30 | $659.00K | $679.00K | (m) | 97.05% |
| 2013-03-31 | $478.19K | $685.00K | (m) | 69.81% |
| 2012-12-31 | $520.19K | $716.00K | (m) | 72.65% |
| 2012-09-30 | $751.00K | $757.00K | (m) | 99.21% |
| 2012-06-30 | $716.00K | $716.00K | (m) | 100.00% |
| 2012-03-31 | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |